BioSpace News Archive

Adaptive therapy provides the ability to personalize patient treatment at the time of treatment based on patient’s anatomy and precise position -- Ethos therapy combines multi-modality images with an artificial intelligence (AI)-driven Adaptive Intelligence™ solution to enable personalized, patient-centric care -- Goshen Center for Cancer Care is the second provider in the United States and the only provider in Indiana to offer Ethos therapy -- The Ethos system’s fa

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and the Cantor Virtual Global Healthcare Conference on September 15, 2020. A live audio webcast of the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in South Korea.

Declares Record Date of September 22, 2020 and Expected Share Distribution Date of October 1, 2020 Conference call with slide presentation today beginning at 4:30 p.m. Eastern time [10-September-2020] INCLINE VILLAGE, Nev. , Sept. 10, 2020 /PRNewswire/ -- PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announced that its Board of Directors has ap

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Cantor Virtual Global Healthcare Conference. Details are as follows: Cantor Virtual Global Healthcare Conference: Date: Thursday, September 17 Time: 8:40 a.m. ET A live webcast

Ultravision™ Controls Aerosolized Particles in Laparoscopic Surgery, Leading to Cleaner Air in the Operating Room

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its management is scheduled to present at the H.C. Wainwright 22 nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Paul Gudonis, chief executive officer an

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced its continued expansion into condition specific dietary supplements with the launch of CV™ Defense, the second of several products to be launched under its new Immunity product line, following the launch of CV™ Acute in August.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in a fireside chat at H.C. Wainwright’s 22 nd Annual Global Investment Healthcare Conference taking place September 14-16, 2020. Dr. Taglietti will also partake in a panel discussion at Maxim’s anti

- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of non-al